Trial Profile

DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody Durvalumab in Combination With Chemotherapy in Patients With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 11 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Capecitabine; Carboplatin; Doxorubicin liposomal; Gemcitabine; Paclitaxel
Indications Advanced breast cancer; Anal cancer; Appendiceal cancer; Colon cancer; Leiomyosarcoma; Nasopharyngeal cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions
Acronyms DURVA+ Study

Most Recent Events

12 Jun 2024 Planned End Date changed from 1 Jun 2024 to 1 Jun 2026.
12 Jun 2024 Planned primary completion date changed from 1 Jun 2024 to 1 Jun 2026.
02 Jun 2023 Planned End Date changed from 1 Jun 2023 to 1 Jun 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com